|
|
|
| Efficacy and safety of CalliSpheres drug-eluting beads prostatic artery chemoembolization in the treatment of advanced prostate cancer with hematuria |
| LIU Song, LIU Meixiao, WANG Qingdong, YU Guangji |
| （Department of Intervention, Linyi Cancer Hospital, Linyi Shandong 276034, China） |
|
|
|
Abstract Objective： To explore the efficacy and safety of CalliSpheres drug-eluting beads prostatic artery chemoembolization （DEB-PACE） in the treatment of advanced prostate cancer with hematuria. Methods： From January 2020 to December 2022, the clinical data of 27 patients with advanced prostate cancer and hematuria admitted to Linyi Cancer Hospital were retrospectively analyzed. All patients received prostatic artery embolization(PAE). The patients were divided into observation group (11 cases) and control group (16 cases) according to different embolic materials. The observation group received DEBPACE (CalliSpheres drugeluting beads loaded with epirubicin of 20~30 mg), the control group were received 8Spheres embolic microspheres. The control of hematuria was observed; the changes of prostate specific antigen, international prostate symptom score, prostate volume, and quality of life QOL scores were compared before and after 2 weeks, 1 month, and 3 months of operation; the hematuria free survival time and overall survival (OS) time of the two groups were recorded; and the treatment related adverse reactions were also recorded. Results： The two groups of patients successfully were completed the corresponding embolization treatment, the technical success rate was 100% (27/27); the success rate of hemostasis was 85.19% (23/27), 90.91% (10/11) in the observation group and 81.25% (13/16) in the control group, with no significant difference（χ2=0.038，P=0.845）； the duration of no hematuria in the observation group were 98 days, higher than that in the control group for 55 days (χ2=22.071, P＜0.001). The prostate specific antigen, prostate volume, international prostate symptom score, and quality of life QOL score of the observation group patients at 2 weeks, 1 month, and 3 months after surgery, as well as the control group patients at 2 weeks and 1 month after surgery, were significantly lower than those before surgery (P<0.05). The control group patients basically recovered to their preoperative levels at 3 months after surgery (P>0.05). The main adverse reactions related to embolization therapy in the two groups were pain, fever, nausea, vomiting, etc. After symptomatic treatment, all main adverse reactions were attenuated without severe complications such as ectopic embolism. There was no significant difference in the adverse reactions between the two groups (P>0.05). By the end of March 1, 2023, the median followup time was 23 months, with an average of (21.89±8.31) months. The median OS in the observation group was 28 months, while in the control group was 20 months. The difference was statistically significant (χ2=5128, P=0024). Conclusion： DEB-PACE is a safe and feasible treatment for advanced prostate cancer with hematuria, which can obtain higher tumor control rate, longer hematuria free survival time and OS.
|
|
Received: 03 April 2023
|
|
|
|
［1］蒋国松, 程功, 阮海龙, 等. 侵犯膀胱颈的T4期前列腺癌根治性手术的疗效分析［J］. 中华泌尿外科杂志, 2021, 42(9): 696-699.
［2］何宜宸, 孙浩, 焦志敏, 等. 前列腺癌相关基因及功能的生物信息学分析［J］. 江苏大学学报（医学版）, 2019, 29(3): 258-263.
［3］Chen JW, Shin JH, Tsao TF, et al. Prostatic arterial embolization for control of hematuria in patients with advanced prostate cancer［J］. J Vasc Interv Radiol, 2017, 28(2): 295-301.
［4］陈涵, 吴德源, 谭远容. 支气管动脉栓塞对治疗大咯血的近期疗效观察及再发危险因素分析［J］. 临床肺科杂志, 2018, 23(7): 1314-1317.
［5］Liu S, Yu G, Wang Q, et al. CalliSpheres microspheres drugeluting bead transhepatic artery chemoembolization with or without sorafenib for the treatment of large liver cancer: a multicenter retrospective study［J］. Am J Transl Res, 2021, 13(12): 13931-13940.
［6］Zhao G, Liu S, Chen S, et al. Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drugeluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients［J］. Drug Deliv, 2021, 28(1): 1356-1362.
［7］李奋强, 苏东君, 李更相, 等. 经支气管动脉和非支气管性体动脉栓塞治疗原发性肺癌咯血临床效果［J］. 介入放射学杂志, 2021, 30(1): 52-56.
［8］FreitesMartinez A, Santana N, AriasSantiago S, et al. Using the common terminology criteria for adverse events(CTCAEVersion 5.0) to evaluate the severity of adverse events of anticancer therapies［J］. Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92.
［9］吴少杰, 蔡森林, 唐仪, 等. 前列腺动脉栓塞术治疗前列腺源性血尿临床效果［J］. 介入放射学杂志, 2022, 31(2): 176-179.
［10］夏维, 徐辉, 张国玺, 等. 超选择性髂内动脉栓塞术治疗晚期前列腺癌合并难治性出血2例报告并文献复习［J］. 现代泌尿外科杂志, 2021, 26(2): 147-150.
［11］Xiaobing L, Meipan Y, Pengfei X, et al. Bronchial artery chemoembolization for hemoptysis in advanced primary lung cancer［J］. Clin Lung Cancer, 2022, 23(3): e203-e209.
［12］叶明, 熊丽琴, 王忆勤, 等. 介入栓塞治疗在高龄难治性前列腺癌出血中的临床效果［J］. 中国老年学杂志, 2019, 39(12): 2887-2889.
［13］全超, 刘红岩, 高伟兴, 等. 前列腺动脉栓塞治疗高危前列腺癌合并尿潴留的疗效观察［J］. 西部医学, 2017, 29(2): 203-206.
［14］Pisco J, Bilhim T, Costa NV, et al. Safety and efficacy of prostatic artery chemoembolization for prostate cancerinitial experience［J］. J Vasc Interv Radiol, 2018, 29(3): 298-305.
［15］Ren K, Wang J, Li Y, et al. The efficacy of drugeluting bead transarterial chemoembolization loaded with oxaliplatin for the treatment of stage ⅢⅣ nonsmallcell lung cancer［J］.Acad Radiol, 2022: S1076-6332(22)00065-4.
［16］吴伟达, 彭建扬, 翁志成, 等. 载药微球栓塞治疗膀胱癌伴出血16例［J］. 介入放射学杂志, 2022, 31(5): 484-488.
［17］Guan Y, Wang W, Zhang T, et al. Epirubicinloaded beads transarterial prostatic arterial chemoembolization is a promising treatment for advanced prostate cancer with lower urinary tract obstruction or hematuriaa case series report［J］. Transl Androl Urol, 2022, 11(4): 480-494.
［18］Wang MQ, Zhang JL, Duan F, et al. Prostate arterial chemoembolization for treatment of refractory hematuria and urinary retention in patients with localized advanced prostate cancer［J］. Prostate Cancer Prostatic Dis, 2023, 26(1): 88-95.
|
|
|
|
